Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + vorolanib in locally advanced or metastatic urothelial carcinoma
ChiCTR2500110574Phase 2Not yet recruiting
- Sponsor
- The Third Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and vorolanib in transitional cell carcinoma (TCC), sponsored by The Third Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: Objective Response Rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sintilimabvorolanib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2500110574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110574.